Partner Roger Strode was quoted in a Chicago Tribune article, “Hospira Stock Soars as Pfizer Says it will Buy for $15.23 Billion,” on February 5, 2015. The article discussed details surrounding pharmaceutical giant Pfizer’s plans to buy Illinois drug maker Hospira. Strode was quoted saying, “The shareholders of Hospira are going to be really well off. Hospira’s stock has zoomed already. It’s a huge benefit to them.”
Strode also touched on the outlook for mergers and acquisitions in the pharmaceutical industry and said, “Pharma has been very robust. A lot of companies have done well and they’re sitting on a lot of cash. We’re still in the middle of a bull market.”
Strode also touched on the outlook for mergers and acquisitions in the pharmaceutical industry and said, “Pharma has been very robust. A lot of companies have done well and they’re sitting on a lot of cash. We’re still in the middle of a bull market.”
People
Related News
April 3, 2026
In the News
David Rosen Weighs in on FDA's Pharma PR Crackdown – 'Stick to the Data'
Foley & Lardner LLP partner David Rosen shared insights on the regulatory challenges pharmaceutical companies face when publicly communicating around new cancer therapies in the MM+M article, “When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio.”
April 2, 2026
In the News
Susan Poll Klaessy and Adrienne Walker Named Chair and Vice Chair of Foley’s Bankruptcy & Business Reorganizations Practice
Foley & Lardner LLP partner Susan Poll Klaessy was appointed chair of the firm’s global Bankruptcy & Business Reorganizations Practice Group. Partner Adrienne Walker will serve as vice chair, supporting the continued growth and strategic direction of the practice.
April 1, 2026
In the News
Foley Featured on Top 10 Sales of 2025 List by Golf Inc.
Foley & Lardner LLP advised on two transactions named among Golf Inc.’s Top 10 Sales of 2025.